CA2441147A1 - Methods of treating disorders of the eye and surrounding tissue with thymosin .beta.4 (t.beta.4), analogues, isoforms and other derivatives - Google Patents

Methods of treating disorders of the eye and surrounding tissue with thymosin .beta.4 (t.beta.4), analogues, isoforms and other derivatives Download PDF

Info

Publication number
CA2441147A1
CA2441147A1 CA002441147A CA2441147A CA2441147A1 CA 2441147 A1 CA2441147 A1 CA 2441147A1 CA 002441147 A CA002441147 A CA 002441147A CA 2441147 A CA2441147 A CA 2441147A CA 2441147 A1 CA2441147 A1 CA 2441147A1
Authority
CA
Canada
Prior art keywords
eye
beta
composition
inhibiting
degeneration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002441147A
Other languages
English (en)
French (fr)
Inventor
Allan L. Goldstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RegeneRx Biopharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2441147A1 publication Critical patent/CA2441147A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA002441147A 2001-03-15 2002-03-14 Methods of treating disorders of the eye and surrounding tissue with thymosin .beta.4 (t.beta.4), analogues, isoforms and other derivatives Abandoned CA2441147A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27564501P 2001-03-15 2001-03-15
US60/275,645 2001-03-15
PCT/US2002/007730 WO2002074193A2 (en) 2001-03-15 2002-03-14 METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN ss4 (Tss4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES

Publications (1)

Publication Number Publication Date
CA2441147A1 true CA2441147A1 (en) 2002-09-26

Family

ID=23053251

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002441147A Abandoned CA2441147A1 (en) 2001-03-15 2002-03-14 Methods of treating disorders of the eye and surrounding tissue with thymosin .beta.4 (t.beta.4), analogues, isoforms and other derivatives

Country Status (8)

Country Link
US (1) US20040131626A1 (enExample)
EP (1) EP1383529A4 (enExample)
JP (2) JP2005506293A (enExample)
CN (2) CN101195025A (enExample)
AU (2) AU2002255736B2 (enExample)
CA (1) CA2441147A1 (enExample)
MX (1) MXPA03008359A (enExample)
WO (1) WO2002074193A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006023879A1 (en) * 2004-08-20 2006-03-02 Board Of Regents, The University Of Texas System Screening of agents for activity against ischemic myocardial insults
WO2006076255A2 (en) * 2005-01-11 2006-07-20 Regenerx Biopharmaceuticals, Inc. Method of treating or preventing microbial eye infection
KR20080021782A (ko) * 2005-06-17 2008-03-07 리지너크스 바이오 파마소티컬스, 인코포레이티드 엘케이케이티이티 및/또는 엘케이케이티엔티 펩티드조성물들 및 그 방법
CN100372572C (zh) * 2005-09-29 2008-03-05 北京诺思兰德生物技术有限责任公司 携带人胸腺素β4基因的重组质粒
US20080132451A1 (en) * 2006-12-01 2008-06-05 Alcon Manufacturing Ltd. Modulation of polysialylated neural adhesion molecules (psa-ncam) as a regulator of ocular disease
EP2260106A4 (en) * 2008-03-17 2011-04-20 Regenerx Biopharmaceuticals IMPROVED BETATHYMOSINFRAGMENTS
JP6202400B2 (ja) 2011-12-12 2017-09-27 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイＴｈｅ Ｂｏａｒｄ Ｏｆ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｉｌｌｉｎｏｉｓ 核酸に関連した眼疾患を治療するための組成物および方法
CN102924573B (zh) * 2012-11-13 2014-07-23 兆科药业（广州）有限公司 一种肌动蛋白结合肽及其用途
WO2016064078A1 (ko) * 2014-10-22 2016-04-28 주식회사 지트리비앤티 티모신 베타 4를 함유하는 조성물 및 이를 포함하는 약학적 제형
KR20170021667A (ko) * 2015-08-18 2017-02-28 주식회사 지트리비앤티 티모신 β4를 유효성분으로 포함하는 신경영양성각막염 치료용 조성물
CA3031069A1 (en) * 2016-07-18 2018-01-25 Regentree, Llc Methods of treating dry eye syndrome
CN106692949B (zh) * 2016-12-23 2022-03-15 北京诺思兰德生物技术股份有限公司 一种用于治疗眼部疾病的药物及其组合物
KR101910908B1 (ko) * 2017-06-14 2018-10-24 (주)휴온스 Gly-Tβ4 (Gly-티모신β4)을 함유하는 안구건조증 치료용 약학적 조성물
CA3083101A1 (en) * 2017-11-24 2019-05-31 G-Treebnt Co., Ltd. Composition for promoting goblet cell proliferation or mucin secretion comprising thymosin beta 4 or derivative thereof as active ingredient
CN113599371A (zh) * 2021-09-06 2021-11-05 郑州大学 二甲双胍在制备预防胸腺退化和/或促进胸腺组织再生药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444757A (en) * 1981-11-16 1984-04-24 Research Corporation Use of thymosin as an anti-diabetes and anti-hypertensive disease agent
US4543340A (en) * 1983-04-07 1985-09-24 George Washington University Radioimmunoassay of thymosin β4
AT401180B (de) * 1990-08-13 1996-07-25 Biomay Biotech Prod Für das baumpollenallergen p14 codierende rekombinante dna-moleküle, daraus hergestellte und abgeleitete polypeptide und deren verwendung
US6124259A (en) * 1993-01-28 2000-09-26 Celtrix Pharmaceuticals, Inc. Method for treating ophthalmic disorders with IGFBP
US5624893A (en) * 1993-10-14 1997-04-29 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment of the cornea following laser irradiation
US5652209A (en) * 1994-04-29 1997-07-29 University Of Miami Use of secretory products of human lacrimal gland acinar epithelia for tear replacement therapy
US6391607B1 (en) * 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
JP3128203B2 (ja) * 1997-02-10 2001-01-29 一男 坪田 分泌腺細胞とリンパ球との接着阻害剤
GB9806632D0 (en) * 1998-03-28 1998-05-27 Stevenson Robert Peptide factor
EP1100529B2 (en) * 1998-07-30 2010-08-25 The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health Thymosin beta 4 promotes wound repair
US20050026165A1 (en) * 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions

Also Published As

Publication number Publication date
JP2005506293A (ja) 2005-03-03
EP1383529A4 (en) 2005-06-29
AU2008261127A1 (en) 2009-01-15
CN100360174C (zh) 2008-01-09
WO2002074193A2 (en) 2002-09-26
JP2009179638A (ja) 2009-08-13
HK1074577A1 (en) 2005-11-18
CN1638789A (zh) 2005-07-13
CN101195025A (zh) 2008-06-11
AU2002255736B2 (en) 2006-08-31
US20040131626A1 (en) 2004-07-08
WO2002074193A3 (en) 2003-12-04
MXPA03008359A (es) 2004-10-15
EP1383529A2 (en) 2004-01-28

Similar Documents

Publication Publication Date Title
AU2008261127A1 (en) Methods for Treating Disorders of the Eye and Surrounding Tissue with Thymosin Beta 4 (TBeta4), Analogues, Isoforms and Other Derivatives
AU2002255736A1 (en) Methods of Treating Disorders of the Eye and Surrounding Tissue with Thymosin Beta4 (TBeta4), Analogues, Isoforms and Other Derivatives
US20110020449A1 (en) Methods of treating disorders of the eye and surrounding tissue with thymosin beta 4 (tb4), analogues, isoforms and other derivatives
GB2369572A (en) Wound treatment composition comprising insulin
US20080096817A1 (en) METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN BETA 4 (Tbeta4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES
JP2009046502A (ja) 皮膚状態の改善を促進するための組成物の製造のための、アミノ酸配列ｌｋｋｔｅｔを含む皮膚変性阻害ポリペプチドの使用
US8716215B2 (en) Method of treating or preventing tissue deterioration, injury or damage due to a neuro-, muscular- or neuro-muscular-degenerative disease, or restore tissue adversely affected by said disease
AU2004308378B2 (en) Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent
AU2006233251B2 (en) Methods for Treating Disorders of the Eye and Surrounding Tissue with Thymosin Beta4 (TBeta4), Analogues, Isoforms and Other Derivatives
AU2002309842B2 (en) Treating epidermlyosis bullosa with thymosin beta 4
AU2002213513A1 (en) Inhibition or reversal of skin aging by actin-sequestering peptides
AU2002309842A1 (en) Treating epidermlyosis bullosa with thymosin beta 4
US20040067227A1 (en) Inhibition or reversal of skin aging by actin-sequestering peptides
HK1074577B (en) THE USE OF THYMOSIN β4 (Tβ4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING DISORDERS OF EYE AND THE SURROUNDING TISSUE
HK1118017A (en) THE USE OF THYMOSIN β4, ANALOGUES, ISOFORMS AND OTHER DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING DISORDERS OF EYE AND THE SURROUNDING TISSUE
US20040170625A1 (en) Methods of treating Epidermolysis Bullosa and associated dermatological indications with thymosin beta 4, analogues, isoforms and other derivatives
WO2006076255A2 (en) Method of treating or preventing microbial eye infection
MXPA06006849A (en) Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued